Response Genetics, a company focused on molecular diagnostic testing services for cancer, announced the recent closing of new payor contracts with four national preferred provider organization (PPO) networks. These four new provider agreements are with America’s Choice Provider Network LLC, FedMed, Inc., Galaxy Health Network, and Prime.
Through these PPO network agreements, Response Genetics’ full suite of precision genetics services are now offered to the health plans, self-insured employers, third party administrators, and other clients participating in these networks. Throughout the United States, Response Genetics can now access 54 million additional people through these new contractual relationships. These new PPO network contracts bring the company’s total to six new such contracts forged this year, opening access to more than 135 million Americans in all.
The predictive genomic testing provided by Response Genetics is chiefly targeted at patients with lung, colon, gastric, and melanoma cancers. The results generated by these testing services give actionable information to treating physicians, guiding therapeutic decisions and allowing for the best therapy on a patient’s specific tumor. The precision of Response Genetics’ services offers a value proposition that is anticipated to improve patient outcomes, boost efficiencies and reduce costs associated with delivering optimal healthcare.
For more information, visit www.responsegenetics.com
About MissionIR
MissionIR is committed to connecting the investment community with companies that have great potential and a strong dedication to building shareholder value. We know our reputation is based on the integrity of our clients and go to great lengths to ensure the companies represented adhere to sound business practices.
Sign up for “The Mission Report” at www.MissionIR.com
Please see disclaimer on the MissionIR website http://www.missionir.com/disclaimer.html
